An investigational oral formulation of octreotide was found to be safe and effective in the treatment of acromegaly in a phase 3 open-label study published online ahead of print in the Journal of Clinical Endocrinology & Metabolism.
Subscribe to "Endo Monitor", the EndocrineWeb eNewsletter for HCPs
If you are not a healthcare professional click here to subscribe to our patient newsletter.